RICHMOND, Va., Nov 08, 2007 (BUSINESS WIRE) -- Insmed Inc. (Nasdaq:INSM), a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs, today announced results for the third quarter and nine-month period ended September 30, 2007.
Revenues for the third quarter ended September 30, 2007 were $1.5 million, up from $226,000 for the corresponding period in 2006. The increase was mainly attributable to improvements in cost recovery from our Expanded Access Program (EAP) to treat patients with amyotrophic lateral sclerosis (ALS). This was partially offset by the revenues lost from our withdrawal of IPLEX(TM) from the short stature market pursuant to the terms of our settlement agreement with Genentech Inc. and Tercica Inc.
The net loss for the third quarter of 2007 was $3.9 million or $0.03 per share, compared with a net loss of $12.4 million or $0.12 per share in the third quarter of 2006. This improvement was attributable to a reduction in selling, general and administrative (SG&A) expenses, which fell to $1.0 million from $7.0 million, a drop in research and development (R&D) expenses to $4.6 million from $5.3 million, and the elimination of cost of goods sold.
The reduction in SG&A was due primarily to reduced litigation expenses and the elimination of commercial expenses associated with our business restructuring plan. The decrease in R&D expenses reflected a reduction in our clinical and commercial manufacturing activity and the elimination of the costs of goods sold resulted from our withdrawal of IPLEX(TM) from the short stature market.
Interest income in the third quarter of 2007 fell to $370,000 from $520,000 in the third quarter of 2006. This was due to the combination of a lower average cash balance on hand and lower interest rates during the most recent quarter. Interest expense quarter on quarter remained the same.
For the first nine months of 2007, revenues totaled $5.4 million, up from $489,000 in the corresponding period of 2006. This increase was due to improvements in the cost recovery from our EAP and the receipt of licensing income from our agreement with NAPO Pharmaceuticals, (NAPO), combined with increased sales of IPLEX(TM) during the first quarter of 2007.
The net loss for the first nine months of 2007 was $16.7 million or $0.15 per share, compared to $34.7 million or $0.37 per share for first nine months of 2006. R&D expenses dropped to $14.4 million from $16.8 million, reflecting lower litigation expenses included in R&D during the first quarter of 2006, and reduced clinical and commercial manufacturing activity. SG&A expenses fell to $7.5 million from $16.0 million, due to a combination of reduced litigation expenses and the elimination of commercial expenses which was partially offset by severance costs associated with our business restructuring plan.
Interest income for the first nine months of 2007 was $0.9 million, compared to $1.4 million for the first nine months of 2006. This decrease was mainly due to lower interest rates and a lower average cash balance for the first nine months of 2007 as compared to the same period in 2006. Interest expense for the first nine months of 2007 was $465,000, compared to $3.2 million for the first nine months of 2006. This decrease in interest expense resulted from lower amortization of the debt discount associated with our March 2005 financing, as an acceleration of the discount took place in the first quarter of 2006 due to the conversion of notes into shares of our common stock.
As of September 30, 2007, we had total cash and cash equivalents on hand of $18.9 million, compared to $24.1 million on hand as of December 31, 2006. The $5.2 million decrease in cash and cash equivalents reflected the use of $22.0 million for operating activities and a $500,000 investment in NAPO. This decrease was partially offset by net proceeds of $17.0 million from an offering of our common stock and warrants to purchase our common stock and $300,000 from a reduced letter of credit.
Investor Conference Call
Insmed will host a conference call on Thursday, November 8, 2007 at 4:30 p.m. Eastern Time to discuss the financial results for the third quarter and nine months ended September 30, 2007, as well as to provide a business update. The call can be accessed live by dialing 877-407-0778 toll free in the United States and Canada, and 201-689-8565 elsewhere.
A telephonic replay of the call will be available approximately two hours afterwards for a period of two weeks at 877-660-6853 from the United States and 201-612-7415, for international callers. The account number is 286 and conference ID number is 259108. On the internet, a replay of the conference call will be available at Insmed's website at www.insmed.com for 90 days.
About Insmed
Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit www.insmed.com. To be added to Insmed's investor lists, please contact Haris Tajyar at htajyar@irintl.com or at 818-382-9702.
Forward-Looking Statements
This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than we do, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow on biologics market may be unsuccessful, our common stock could be delisted from the Nasdaq Global Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
